Home
/
ADMA BIOLOGICS, INC.
/
Financials
/
Quarterly
ADMA BIOLOGICS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that ADMA BIOLOGICS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2021
Mar 31, 2021
$16.05M
May 12, 2021
Q3
2020
Sep 30, 2020
$10.28M
Nov 5, 2020
Q2
2020
Jun 30, 2020
$7.79M
Aug 5, 2020
Q1
2021
Mar 31, 2020
$10.20M
May 12, 2021
Q3
2020
Sep 30, 2019
$7.22M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$6.56M
Aug 5, 2020
Q1
2020
Mar 31, 2019
$3.53M
May 6, 2020
Q3
2019
Sep 30, 2018
$4.23M
Nov 6, 2019
Q2
2019
Jun 30, 2018
$4.66M
Aug 8, 2019
Q1
2019
Mar 31, 2018
$4.04M
May 8, 2019
Q3
2018
Sep 30, 2017
$4.73M
Nov 9, 2018
Q2
2018
Jun 30, 2017
$3.40M
Aug 10, 2018
Q1
2018
Mar 31, 2017
$2.63M
May 14, 2018
Q3
2017
Sep 30, 2016
$2.94M
Nov 3, 2017
Q2
2017
Jun 30, 2016
$2.27M
Aug 11, 2017
Q1
2017
Mar 31, 2016
$2.12M
May 12, 2017
Q3
2016
Sep 30, 2015
$1.85M
Nov 10, 2016
Q2
2016
Jun 30, 2015
$1.31M
Aug 12, 2016
Q1
2016
Mar 31, 2015
$1.50M
May 13, 2016
Q3
2015
Sep 30, 2014
$1.37M
Nov 10, 2015
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$134.22M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$121.98M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$114.80M
May 7, 2025
Q3
2025
Sep 30, 2024
$119.84M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$107.19M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$81.88M
May 7, 2025
Q3
2024
Sep 30, 2023
$67.28M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$60.12M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$56.91M
May 9, 2024
Q3
2023
Sep 30, 2022
$41.09M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$33.91M
Aug 9, 2023
Q1
2023
Mar 31, 2022
$29.10M
May 10, 2023
Q3
2022
Sep 30, 2021
$20.68M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$17.83M
Aug 10, 2022
Q1
2022
Mar 31, 2021
$16.05M
May 11, 2022
Q3
2021
Sep 30, 2020
$10.28M
Nov 10, 2021
Q2
2021
Jun 30, 2020
$7.79M
Aug 11, 2021
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$36.43M
Nov 5, 2025
Q3
2025
Jun 30, 2025
$34.22M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$34.22M
Aug 6, 2025
Q3
2025
Mar 31, 2025
$26.90M
Nov 5, 2025
Q1
2025
Mar 31, 2025
$26.90M
May 7, 2025
Q2
2025
Mar 31, 2025
$26.90M
Aug 6, 2025
Q3
2025
Sep 30, 2024
$35.91M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$32.06M
Aug 6, 2025
Q3
2025
Jun 30, 2024
$32.06M
Nov 5, 2025
Q2
2025
Mar 31, 2024
$17.81M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$17.81M
May 7, 2025
Q3
2025
Mar 31, 2024
$17.81M
Nov 5, 2025
Q3
2024
Sep 30, 2023
$2.57M
Nov 7, 2024
Q2
2024
Jun 30, 2023
($6.37M)
Aug 8, 2024
Q3
2024
Jun 30, 2023
($6.37M)
Nov 7, 2024
Q3
2024
Mar 31, 2023
($6.79M)
Nov 7, 2024
Q1
2024
Mar 31, 2023
($6.79M)
May 9, 2024
Q2
2024
Mar 31, 2023
($6.79M)
Aug 8, 2024
Q3
2023
Sep 30, 2022
($14.90M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($13.76M)
Aug 9, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$51.01M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$42.80M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$34.88M
May 7, 2025
Q3
2025
Sep 30, 2024
$39.64M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$39.20M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$21.82M
May 7, 2025
Q3
2024
Sep 30, 2023
$8.69M
Nov 7, 2024
Q2
2024
Jun 30, 2023
($473.0K)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($813.0K)
May 9, 2024
Q3
2023
Sep 30, 2022
($9.32M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($9.17M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($14.82M)
May 10, 2023
Q3
2022
Sep 30, 2021
($14.44M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($15.58M)
Aug 10, 2022
Q1
2022
Mar 31, 2021
($15.16M)
May 11, 2022
Q3
2021
Sep 30, 2020
($13.80M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($17.12M)
Aug 11, 2021
Q1
2021
Mar 31, 2020
($16.77M)
May 12, 2021
Q3
2020
Sep 30, 2019
($9.05M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($11.34M)
Aug 5, 2020